Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

[1]  Y. Sakai,et al.  Targeting metabolic reprogramming in KRAS-driven cancers , 2017, International Journal of Clinical Oncology.

[2]  M. Sarabi,et al.  Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. , 2017, Oncology letters.

[3]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2017, with focus on lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Xianjun Yu,et al.  Critical role of oncogenic KRAS in pancreatic cancer (Review). , 2016, Molecular medicine reports.

[5]  Sudhir Kumar Jain,et al.  Recent developments in L-asparaginase discovery and its potential as anticancer agent. , 2016, Critical reviews in oncology/hematology.

[6]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[7]  J. Emile,et al.  Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma , 2015, Pancreas.

[8]  B. Dörken,et al.  Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Kalmanti,et al.  Expression levels of ASNS in mesenchymal stromal cells in childhood acute lymphoblastic leukemia , 2014, International Journal of Hematology.

[10]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[11]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[12]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[13]  S. Hunger,et al.  Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines , 2008, Pediatric blood & cancer.

[14]  M. Asaka,et al.  Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. , 2007, Cancer research.

[15]  M. D. Den Boer,et al.  Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. , 2006, Blood.

[16]  J. Boos,et al.  Unphysiological effects contributing to asparaginase toxicity in vitro. , 1998, The American journal of physiology.

[17]  S. Schuster,et al.  Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. , 1997, American Journal of Physiology.